INTRODUCTION: This study aimed to determine the etiological distribution of patients treated for precocious puberty and to compare the results of gonadotropin-releasing hormone (GnRH) analog treatment with clinical and laboratory data during the administration and follow-up period.
METHODS: The files of patients treated with a diagnosis of precocious puberty between October 2016 and July 2019 in the pediatric endocrinology outpatient clinic were retrospectively analyzed.
RESULTS: While 39 (88.6%) of our patients with precocious puberty were female, five (11.4%) were male. True precocious puberty (TPP) was found in 42 patients (95.5%) and combined precocious puberty (CPP) in two patients (4.5%). While 37 (88.1%) of TPP patients were diagnosed with idiopathic precocious puberty, an organic cause was found in five patients. Both of the patients treated for CPP had late-onset congenital adrenal hyperplasia. The mean estimated adult height (EAH) before the treatment was 151.88±6.77 cm in our patients between the ages of 6 and 8 who were started on GnRH analog treatment with a diagnosis of TPP, while the mean EAH after treatment was 155.16±7.82 cm (p<0.001). An increase in body mass index-standard deviation score was found in patients who received triptorelin acetate treatment, but no statistically significant difference was found.
DISCUSSION AND CONCLUSION: Precocious puberty is more common in girls, and idiopathic TPP constitutes the majority of cases. GnRH analog treatment may contribute positively to the EAHs of girls with TPP, especially those younger than 8 years old.